Are you forgetting all the game theory discussed about the T-enox approval scenario? The market goes from 2 entrants to 4 as Sanofi launches an AG. Yes, pricing will be aggressive, but the notion of Teva taking the majority of the market is a definite stretch: They are not against just Momenta, they are against Sandoz, which will be getting entrenched. I want some of what that analyst is smoking.
Regards, RockRat
Market Data 
Markets 
AI
